Biopharmaceutical company TG Therapeutics (TGTX.US) stock price plummeted, Q1 profits fell short of expectations.

According to the financial news app, Smart Finance, on Monday, the stock price of the biopharmaceutical company TG Therapeutics (TGTX.US) fell by nearly 15% in early trading in the US stock market. In terms of news, TG Therapeutics' financial report for the first quarter of 2025 showed that Q1 revenue was $121 million, a year-on-year increase of 90.4%, which was $3 million higher than analyst expectations; GAAP earnings per share were $0.03, which was $0.14 lower than analyst expectations.